Trial Profile
A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Theracos
- 13 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2009 New trial record